GFAP and Alzheimer disease: We evaluated how plasma biomarkers of AD (p‐tau181), astrocyte reactivity (GFAP), and neurodegeneration (NfL) related to clinical diagnosis and Aβ‐PET in a large cohort of HW and NHW older adults.